Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers

Phase 2HMBD-001CetuximabPositive

AI Analysis

Summary

Hummingbird Bioscience announced the first patient dosed in a Phase II trial evaluating HMBD-001 combined with cetuximab for advanced squamous cell cancers.

Clinical Trial Data

Phase

Phase II

Outcome Details

First patient dosed

Importance:5/10

Sentiment:

0.50

Phase 2OncologySquamous cell carcinomaClinical trial initiation

Related Companies

$BHIC $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 30, 2026 9:00 AM

Read Original